Pfizer Deal To Help Propel Aurobindo's Revenues To $2 Billion In Three Years
This article was originally published in PharmAsia News
Executive Summary
HYDERABAD, India - With fifteen manufacturing sites under its belt and a comprehensive outsourcing deal with Pfizer, India's Aurobindo Pharma expects to see a huge bounce in its revenues from the present $800 million to over $2 billion in a span of three years